Differences in weight loss and health outcomes among African Americans and whites in multicentre trials

Obesity Reviews

Volumn 15, Issue , 2014, Pages 46-61

  Wingo, B C ^a   Carson, T L ^a   Ard, J ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; Multicentre trials; Weight loss

Indexed keywords

AFRICAN AMERICAN; BLOOD PRESSURE; COMPARATIVE STUDY; DIABETES MELLITUS; ETHNIC GROUP; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MULTICENTER STUDY (TOPIC); RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; WEIGHT CHANGE; WEIGHT REDUCTION; ATTITUDE TO HEALTH; BLOOD; CAUCASIAN; DIABETES MELLITUS, TYPE 2; ETHNOLOGY; HEALTH BEHAVIOR; METABOLISM; OBESITY; PREVENTIVE HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; TRIACYLGLYCEROL;

AFRICAN AMERICANS; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; MULTICENTER STUDIES AS TOPIC; OBESITY; PREVENTIVE HEALTH SERVICES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES; WEIGHT LOSS;

EID: 84908386538     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12212     Document Type: Review

References (77)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among us adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
2. Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey, 2010. National Center for Health Statistics. Vital Health Stat 10(252). 2012.
3. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2011.
4. Centers for Disease Control and Prevention. National Center for Health Statistics, Division of Health Interview Statistics. 2012.
5. Centers for Disease Control and Prevention. High Blood Pressure Facts. 2012. http://www.cdc.gov/bloodpressure/facts.htm URL (accessed August 2012).
6. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136: 493-503.
7. Knowler WC, Barrett-Connor E, Fowler SE etal. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
8. Foster GD, Makris AP, Bailer BA. Behavioral treatment of obesity. Am J Clin Nutr 2005; 82(Suppl.): 230S-235S.
9. Wing RR. Behavioral weight control. In: Wadden TA, Stunkard AJ (eds). Handbook of Obesity Treatment. Guilford Press: New York, 2002, pp. 301-316.
10. Elmer PJ, Obarzanek E, Vollmer WM etal. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144: 485-495.
11. Appel LJ, Champagne CM, Harsha DW etal. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289: 2083-2093.
12. Ojha RP, Thertulien R, Fischback LA. Racial under-representation in clinical trials: consequence, myth, and proposition. Epi Focus 2008; 1: e2.
13. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services, Task Force. Ann Intern Med 2011; 155: 434-447.
14. Higgins JP, Altman DG, Gotzsche PC etal. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
15. Schatzkin A, Lanza E, Freedman LS etal. The polyp prevention trial I: Rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev 1996; 5: 375-383.
16. Subak LL, Wing R, West DS etal. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009; 360: 481-490.
17. Foster GD, Borradaile KE, Vander Veur SS etal. The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study. Postgrad Med 2009; 121: 113-118.
18. Heshka S, Anderson JW, Atkinson RL etal. Weight loss with self-help compared with a structured commercial program: a randomized trial. JAMA 2003; 289: 1792-1798.
19. Jakicic JM, Tate DF, Lang W etal. Effect of a stepped-care intervention approach on weight loss in adults: a randomized clinical trial. JAMA 2012; 307: 2617-2626.
20. Sacks FM, Bray GA, Carey VJ etal. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360: 859-873.
21. The Treatment of Mild Hypertension Research Group. The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 1991; 151: 1413-1423.
22. Foy CG, Lewis CE, Hairston KG etal. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Obesity (Silver Spring) 2011; 19: 83-93.
23. Fredheim JM, Rollheim J, Sandbu R etal. Obstructive sleep apnea after weight loss: a clinical trial comparing gastric bypass and intensive lifestyle intervention. J Clin Sleep Med 2013; 9: 427-432.
24. Jeffery RW, Tonascia S, Bjornson-Benson W, Schlundt DG, Sugars C. Treatment in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials 1989; 10(3 Suppl.): 65S-83S.
25. Ledikwe JH, Rolls BJ, Smiciklas-Wright H etal. Reductions in dietary energy density are associated with weight loss in overweight and obese participants in the PREMIER trial. Am J Clin Nutr 2007; 85: 1212-1221.
26. McGuire HL, Svetkey LP, Harsha DW, Elmer PJ, Appel LJ, Ard JD. Comprehensive lifestyle modification and blood pressure control: a review of the PREMIER trial. J Clin Hypertens (Greenwich) 2004; 6: 383-390.
27. Svetkey LP, Erlinger TP, Vollmer WM etal. Effect of lifestyle modifications on blood pressure by race, sex, hypertension status, and age. J Hum Hypertens 2005; 19: 21-31.
28. Svetkey LP, Harsha DW, Vollmer WM etal. Premier: a clinical trial of comprehensive lifestyle modification for blood pressure control: rationale, design and baseline characteristics. Ann Epidemiol 2003; 13: 462-471.
29. Albu JB, Heilbronn LK, Kelley DE etal. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes 2010; 59: 627-633.
30. Espeland MA, Bray GA, Neiberg R etal. Describing patterns of weight changes using principal components analysis: results from the Action for Health in Diabetes (Look AHEAD) research group. Ann Epidemiol 2009; 19: 701-710.
31. Look AHEAD Research Group, Bray G, Gregg E etal. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res 2006; 3: 202-215.
32. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G etal. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-1383.
33. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575.
34. Unick JL, Beavers D, Jakicic JM etal. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 2011; 34: 2152-2157.
35. Wadden TA, Neiberg RH, Wing RR etal. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) 2011; 19: 1987-1998.
36. Wadden TA, Neiberg RH, Wing RR etal. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) 2011; 19: 1987-1998.
37. Wing RR, Lang W, Wadden TA etal. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481-1486.
38. Appel LJ, Espeland M, Whelton PK etal. Trial of Nonpharmacologic Intervention in the Elderly (TONE). Design and rationale of a blood pressure control trial. Ann Epidemiol 1995; 5: 119-129.
39. Appel LJ, Espeland MA, Easter L etal. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001; 161: 685-693.
40. Kostis JB, Espeland MA, Appel L etal. Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? Trial of Nonpharmacologic Interventions in the Elderly (TONE) Cooperative Research Group. Am J Cardiol 1998; 82: 1501-1508.
41. Kumanyika SK, Espeland MA, Bahnson JL etal. Ethnic comparison of weight loss in the Trial of Nonpharmacologic Interventions in the Elderly. Obes Res 2002; 10: 96-106.
42. Whelton PK, Appel LJ, Espeland MA etal. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279: 839-846.
43. Whelton PK, Babnson J, Appel LJ etal. Recruitment in the Trial of Nonpharmacologic Intervention in the Elderly (TONE). J Am Geriatr Soc 1997; 45: 185-193.
44. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999; 22: 623-634.
45. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000; 23: 1619-1629.
46. Diabetes Prevention Research Group. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity (Silver Spring) 2006; 14: 2107-2117.
47. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE etal. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.
48. Hamman RF, Wing RR, Edelstein SL etal. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29: 2102-2107.
49. Ratner R, Goldberg R, Haffner S etal. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005; 28: 888-894.
50. Rubin RR, Fujimoto WY, Marrero DG etal. The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials 2002; 23: 157-171.
51. West DS, Elaine Prewitt T, Bursac Z etal. Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring) 2008; 16: 1413-1420.
52. Whelton PK, Appel LJ, Charleston J etal. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992; 267: 1213-1220.
53. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157: 657-667.
54. Appel LJ, Hebert PR, Cohen JD etal. Baseline characteristics of participants in phase II of the Trials of Hypertension Prevention (TOHP II). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 149-155.
55. Cook NR, Kumanyika SK, Cutler JA. Effect of change in sodium excretion on change in blood pressure corrected for measurement error. The Trials of Hypertension Prevention, Phase I. Am J Epidemiol 1998; 148: 431-444.
56. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35: 544-549.
57. Hebert PR, Bolt RJ, Borhani NO etal. Design of a multicenter trial to evaluate long-term life style intervention in adults with high-normal blood pressure levels. Trials of Hypertension Prevention (phase II). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 130-139.
58. Hollis JF, Satterfield S, Smith F etal. Recruitment for phase II of the Trials of Hypertension Prevention. Effective strategies and predictors of randomization. Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 140-148.
59. Kumanyika SK, Cook NR, Cutler JA etal. Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II. J Hum Hypertens 2005; 19: 33-45.
60. Lasser VI, Raczynski JM, Stevens VJ etal. Trials of Hypertension Prevention, phase II. Structure and content of the weight loss and dietary sodium reduction interventions. Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 156-164.
61. Satterfield S, Borhani NO, Whelton P etal. Recruitment for phase I of the trials of hypertension prevention. Am J Prev Med 1993; 9: 237-243.
62. Satterfield S, Cutler JA, Langford HG etal. Trials of hypertension prevention. Phase I design. Ann Epidemiol 1991; 1: 455-471.
63. Stevens VJ, Corrigan SA, Obarzanek E etal. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153: 849-858.
64. Stevens VJ, Obarzanek E, Cook NR etal. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1-11.
65. Whelton PK, Buring J, Borhani NO etal. The effect of potassium supplementation in persons with a high-normal blood pressure. Results from phase I of the Trials of Hypertension Prevention (TOHP). Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 85-95.
66. Brown KM, Oberman A, Van Natta ML etal. Baseline characteristics in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials 1989; 10(3 Suppl.): 40S-64S.
67. Funk KL, Elmer PJ, Stevens VJ etal. Premier - a trial of lifestyle interventions for blood pressure control: Intervention design and rationale. Health Promot Pract 2008; 9: 271-280.
68. Wadden TA, West DS, Delahanty L etal. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring) 2006; 14: 737-752.
69. Meinert CL, Borhani NO, Langford HG. Design, methods, and rationale in the Hypertension Prevention Trial. Hypertension Prevention Trial Research Group. Control Clin Trials 1989; 10(3 Suppl.): 1S-29S.
70. Svetkey LP, Ard JD, Stevens VJ etal. Predictors of long-term weight loss in adults with modest initial weight loss, by sex and race. Obesity (Silver Spring) 2011; 20: 1820-1828.
71. Kumanyika SK, Obarzanek E, Stevens VJ, Hebert PR, Whelton PK. Weight-loss experience of black and white participants in NHLBI-sponsored clinical trials. Am J Clin Nutr 1991; 53(6 Suppl.): 1631S-1638S.
72. Hunter GR, Weinsier RL, Darnell BE, Zuckerman PA, Goran MI. Racial differences in energy expenditure and aerobic fitness in premenopausal women. Am J Clin Nutr 2000; 71: 500-506.
73. Albu J, Shur M, Curi M, Murphy L, Heymsfield SB, Pi-Sunyer FX. Resting metabolic rate in obese, premenopausal black women. Am J Clin Nutr 1997; 66: 531-538.
74. Weyer C, Snitker S, Bogardus C, Ravussin E. Energy metabolism in African Americans: potential risk factors for obesity. Am J Clin Nutr 1999; 70: 13-20.
75. Ard JD, Cox TL, Zunker C, Wingo BC, Jefferson BK, Brakhage C. A study of a culturally enhanced EatRight dietary intervention in a predominately African American workplace. J Public Health Manag Pract 2010; 16: E1-E8.
76. Ackermann RT, Finch EA, Caffrey HM, Lipscomb ER, Hays LM, Saha C. Long-term effects of a community-based lifestyle intervention to prevent type 2 diabetes: the DEPLOY extension pilot study. Chronic Illn 2011; 7: 279-290.
77. Finch EA, Kelly MS, Marrero DG, Ackermann RT. Training YMCA wellness instructors to deliver an adapted version of the Diabetes Prevention Program lifestyle intervention. Diabetes Educ 2009; 35: 224-228, 232.